Comment from LUNGevity Foundation

Summary: The LUNGevity Foundation, a lung cancer nonprofit, supports the draft guidance on using AI in regulatory decision-making for drug and biological products. They recommend providing more specific guidance on early consultation with the FDA, methodological transparency (including an optional template), defining the context of use across different programs, and clarifying risk assessment and performance evaluation metrics.